Acute pancreatitis is an acute inflammatory disorder of the pancreas, sometimes involving surrounding tissues and distant organs. It typically presents with sudden, persistent upper abdominal pain and elevated pancreatic enzymes in the blood. Most episodes resolve without lasting structural damage, but a minority produce pancreatic necrosis, infected tissue, or prolonged failure of the respiratory, cardiovascular, or renal systems. Gallstones and alcohol exposure are the leading causes in many populations.
The disease is an important cause of emergency hospital admission for gastrointestinal illness. Its clinical course depends less on the intensity of abdominal symptoms than on the development and duration of organ failure and the presence of complications. Modern classification distinguishes the severity of an episode from its anatomical appearance, while treatment has shifted toward carefully monitored supportive care, early feeding, selective treatment of biliary obstruction, and delayed, minimally invasive intervention for necrotic complications.
Disease burden and clinical patterns
Acute pancreatitis is one of the most frequent pancreatic diseases and a major cause of hospitalization within the digestive system. Population-based studies commonly report an annual incidence of approximately 20–50 cases per 100,000 people, although estimates vary substantially by country, age distribution, diagnostic practice, and case ascertainment. Rates have risen in many regions. Increasing gallstone disease, metabolic risk factors, population aging, and improved recognition contribute to this pattern, but their relative importance differs between populations.
The distribution of causes varies geographically and demographically. Biliary pancreatitis is particularly frequent in populations with a high burden of gallstones, whereas alcohol-associated disease constitutes a larger proportion of cases in some younger and middle-aged adult populations. Neither cause is confined to a particular sex or age group. Severe hypertriglyceridemia accounts for a smaller but clinically important share of cases and is especially prominent in selected metabolic and pregnancy-associated presentations. Drug-related, postprocedural, hereditary, and unexplained cases account for additional disease burden.
Approximately four fifths of episodes follow a relatively mild course, although the proportion depends on referral patterns and the classification used. Mortality in mild disease is very low. Across hospitalized populations, overall in-hospital mortality is generally in the low single digits, but this average conceals the much higher risk associated with persistent organ failure. Tertiary referral centers often report higher mortality because they receive patients with extensive necrosis, infection, or prolonged critical illness. Comparisons between studies therefore require attention to case mix rather than mortality figures alone.
A single episode is not always an isolated event. Recurrent attacks may occur when a precipitating factor remains present, particularly untreated gallstone disease, continuing alcohol exposure, severe lipid disorders, or inherited susceptibility. Recurrent acute pancreatitis and chronic pancreatitis overlap biologically but are not interchangeable diagnoses: recurrent disease describes separate acute attacks, whereas chronic disease involves persistent structural injury, often including fibrosis, ductal abnormalities, and progressive loss of function. An apparently recovered patient may also retain metabolic or digestive consequences after only one attack.
Causes and predisposing factors
Biliary pancreatitis usually begins when a migrating gallstone or biliary sludge transiently obstructs the shared outlet of the bile and pancreatic ducts near the duodenum. The offending stone may pass before imaging occurs, leaving no persistent obstruction. Consequently, absence of a common bile duct stone on an initial scan does not exclude a biliary cause. Small stones can be particularly important because they can migrate through the cystic duct and lodge at the ampulla. Coexisting gallbladder stones, abnormal liver biochemical tests, and bile duct findings help establish the likely mechanism.
Alcohol-associated pancreatitis reflects a combination of direct cellular toxicity, altered secretion, and susceptibility rather than a simple immediate response to any alcohol exposure. Prolonged heavy consumption is a common setting, but only a minority of heavily exposed individuals develop pancreatitis. Smoking and genetic factors modify risk. Alcohol can increase the vulnerability of pancreatic acinar cells to abnormal calcium signaling and mitochondrial injury, while repeated injury may promote progression toward chronic pancreatic disease.
Severe hypertriglyceridemia is another established cause. A causal contribution becomes particularly plausible when triglycerides exceed approximately 1,000 mg/dL, equivalent to 11.3 mmol/L, although there is no absolute threshold separating causal from incidental elevation. Pancreatic lipase can release toxic concentrations of unbound fatty acids from triglyceride-rich particles, while highly lipemic blood may impair microcirculation. Poorly controlled diabetes mellitus, alcohol exposure, inherited lipid disorders, certain medicines, and pregnancy can contribute to this metabolic setting. Hypercalcemia is a less common metabolic cause.
Pancreatitis can follow endoscopic retrograde cholangiopancreatography, abdominal trauma, or pancreatic surgery. Postprocedural disease may result from mechanical injury, edema at the pancreatic outlet, hydrostatic stress, or other procedural factors. Numerous medicines have been associated with pancreatitis, but the strength of evidence varies considerably; temporal coincidence alone does not establish causation. Azathioprine and some other agents have relatively well-established associations. Less frequent causes include selected infections, autoimmune pancreatic disease, ductal obstruction, and anatomical abnormalities.
An episode is termed idiopathic when an appropriate investigation does not establish its cause. This category can contain occult biliary sludge, small tumors, unrecognized medication effects, or genetic predisposition. Variants in genes including PRSS1, SPINK1, CFTR, and CTRC influence pancreatic enzyme regulation or ductal physiology, particularly in early-onset or recurrent disease. Pancreatic cancer can occasionally first manifest as acute pancreatitis through ductal obstruction. Thus, “idiopathic” describes the state of etiological knowledge rather than a single biological disease.
Cellular injury and systemic inflammation
The pancreas normally produces digestive enzymes while protecting itself from their destructive effects. Acinar cells synthesize many proteolytic enzymes as inactive precursors, package them into secretory granules, and release them into the ductal system. Ductal cells provide bicarbonate-rich fluid that supports transport and establishes conditions for intestinal digestion. Compartmentalization, intracellular enzyme inhibitors, and controlled activation in the intestine help prevent pancreatic self-injury.
An important early event in many forms of acute pancreatitis is sustained abnormal intracellular calcium elevation in acinar cells. This differs from the brief, localized calcium signals involved in normal secretion. Excessive calcium loading can impair mitochondria, reduce adenosine triphosphate production, and disrupt membrane transport. Disturbed intracellular trafficking and defective disposal of damaged cellular material bring digestive enzyme precursors into abnormal contact with activating enzymes. Premature activation of trypsin contributes to injury, but the disease cannot be explained solely as uncontrolled enzymatic digestion.
Inflammatory pathways can be activated alongside, and partly independently of, trypsin activation. Injured acinar cells release signals that recruit neutrophils, macrophages, and other components of the immune system. Cytokines, chemokines, reactive oxygen species, and vascular mediators amplify local inflammation. Pancreatic lipase also injures surrounding fat, producing fat necrosis and releasing fatty acids that may worsen cellular and systemic toxicity. Disturbed pancreatic microcirculation further reduces oxygen delivery and favors necrosis.
When the inflammatory response extends beyond the pancreas, increased vascular permeability allows fluid to move from the circulation into tissues and body cavities. This process can reduce effective circulating volume even when total body fluid is increased. Pulmonary endothelial injury may impair gas exchange; renal hypoperfusion and inflammation may impair kidney function; and profound vasodilation may compromise blood pressure. Systemic inflammation can therefore cause organ failure before any infection develops. Early fever, tachycardia, or leukocytosis does not by itself establish a bacterial complication.
Intestinal dysfunction provides an additional connection between local injury and later complications. Reduced gut perfusion, impaired motility, altered microbial ecology, and loss of barrier integrity may facilitate migration of intestinal microorganisms into necrotic tissue. Infection of pancreatic or peripancreatic necrosis usually develops later than the initial inflammatory insult. Proinflammatory activity can coexist with impaired host defense, helping explain why the same illness may produce both severe sterile inflammation and susceptibility to subsequent infection.
Clinical presentation and diagnostic criteria
The characteristic symptom is acute, persistent epigastric pain, often severe and sometimes radiating through to the back. The pain may be accompanied by nausea, vomiting, abdominal tenderness, and reduced bowel activity. Its location and severity vary, and older adults or critically ill patients may have less typical presentations. Tachycardia, fever, hypotension, and respiratory distress reflect the systemic response or complications rather than defining the diagnosis. Rare discoloration around the umbilicus or flanks can occur with retroperitoneal bleeding, but these signs are neither common nor specific.
The internationally accepted diagnostic framework requires at least two of three findings: characteristic abdominal pain; serum lipase or amylase activity at least three times the upper limit of normal; and characteristic findings on imaging. When typical pain and sufficiently elevated enzymes are both present, cross-sectional imaging is not necessary simply to establish the diagnosis. Conversely, imaging can be important when symptoms are atypical, enzyme results are equivocal, or another abdominal emergency is possible.
Serum lipase is generally more useful than amylase because it is more pancreas-associated and remains elevated longer. Neither test is perfectly specific: elevated lipase can accompany renal impairment, intestinal ischemia, and other illnesses. Enzyme activity may be less striking in delayed presentations or some hypertriglyceridemic episodes. The magnitude of lipase or amylase elevation does not reliably indicate disease severity, and repeated measurement after diagnosis does not provide a dependable measure of recovery. A falling enzyme level can coexist with worsening organ failure or evolving necrosis.
The differential diagnosis includes perforated peptic ulcer, acute cholecystitis, bowel obstruction, mesenteric ischemia, myocardial infarction, and aortic disease. Diabetic ketoacidosis can produce abdominal pain and elevated pancreatic enzymes without necessarily indicating pancreatitis, although the conditions can coexist. Clinical assessment therefore combines the symptom pattern with examination, biochemical findings, and selective imaging rather than treating one abnormal laboratory result as conclusive.
Early investigation also addresses cause and physiological impact. Liver tests and abdominal ultrasonography help identify biliary disease; triglycerides and calcium can reveal metabolic causes. A complete blood count, renal function tests, electrolytes, glucose, and oxygenation measurements characterize systemic disturbance. Rising blood urea nitrogen and persistent hemoconcentration can accompany inadequate perfusion, but each must be interpreted in context. Clinical diagnosis, causal attribution, and severity assessment are related but separate tasks.
Imaging and local anatomical complications
Imaging distinguishes two principal morphological forms: interstitial edematous pancreatitis and necrotizing pancreatitis. In interstitial disease, the gland is inflamed and enlarged but retains tissue enhancement after intravenous contrast administration. In necrotizing disease, portions of the pancreatic parenchyma, surrounding tissues, or both become nonviable. Necrosis may evolve over several days, so an early scan can underestimate its extent. Anatomical severity and physiological severity are not identical: substantial organ failure can occur without extensive necrosis, and some patients with necrosis initially remain physiologically stable.
Contrast-enhanced computed tomography is particularly useful for evaluating necrosis, collections, and complications when the clinical course warrants it. Routine immediate scanning adds little when the diagnosis is already clear and the patient is improving. Imaging after approximately 72 hours from symptom onset often characterizes necrosis more accurately than very early imaging. Magnetic resonance imaging can provide complementary information about fluid, solid debris, and pancreatic ducts. Magnetic resonance cholangiopancreatography and endoscopic ultrasound can investigate suspected ductal stones or otherwise unexplained disease.
The revised Atlanta classification separates collections by their contents, wall formation, and timing. An acute peripancreatic fluid collection occurs in interstitial edematous pancreatitis, usually within the first four weeks. It contains fluid without necrotic material and lacks a mature wall. A pancreatic pseudocyst is a well-defined, encapsulated fluid collection with little or no solid necrotic content, usually developing after approximately four weeks. Many early fluid collections resolve without becoming pseudocysts.
Necrotizing pancreatitis produces different collections. An acute necrotic collection contains variable amounts of fluid and nonviable tissue and lacks a fully developed wall. Walled-off necrosis is an encapsulated collection of necrotic material that generally develops after about four weeks. These time boundaries describe typical maturation rather than an exact biological deadline. The distinction between a pseudocyst and walled-off necrosis matters because solid debris changes drainage requirements and procedural risk; older literature sometimes used these terms less precisely.
Additional complications include obstruction of the stomach or bile duct, pancreatic duct disruption, and abdominal or thoracic fluid leakage. Splenic, portal, or mesenteric venous thrombosis may occur. Inflammation can erode an arterial wall and produce a pseudoaneurysm, which may bleed into a collection or the gastrointestinal tract. Excessive intra-abdominal pressure can impair ventilation and organ perfusion. Imaging describes these complications, but the presence of a collection or necrosis alone does not establish a need for intervention.
Severity classification and prediction
The revised Atlanta classification, developed through international consensus and published in 2013, defines three severity categories. Mild acute pancreatitis has no organ failure and no local or systemic complications. Moderately severe disease includes transient organ failure lasting no more than 48 hours, local complications, or exacerbation of a pre-existing medical condition, without persistent organ failure. Severe acute pancreatitis is defined by organ failure persisting for more than 48 hours. Failure of one organ system is sufficient for the severe category; multiple-organ failure carries an especially high risk.
Organ failure is commonly operationalized using the modified Marshall scoring system, which assesses respiratory, renal, and cardiovascular function. A score of at least two in any system meets its organ-failure threshold. Oxygenation, serum creatinine, and blood pressure response to fluids contribute to this assessment. The emphasis on duration is important: a brief physiological disturbance that resolves rapidly differs prognostically from a sustained disturbance, even if the initial measurements appear similar.
The illness is often described as having an early and a late phase. The early phase, usually concentrated in the first week, is dominated by the systemic inflammatory response and evolving organ dysfunction. A later phase occurs principally in moderately severe or severe disease and is characterized by persistent inflammation, local complications, or infection. These phases overlap rather than forming a rigid timetable. Infection can develop while organ failure persists, and sterile necrosis can remain clinically significant for weeks.
Several tools estimate the risk of an unfavorable course. Ranson criteria combine admission findings with measurements obtained during the first 48 hours. APACHE II assesses broader physiological disturbance and can be recalculated. BISAP, developed using large clinical datasets, incorporates blood urea nitrogen, impaired mental status, systemic inflammatory response, age, and pleural effusion. Computed tomography severity indices assess anatomical abnormalities. Each tool serves a different purpose, and no score perfectly predicts an individual course or replaces repeated clinical assessment.
Persistent systemic inflammatory response, rising blood urea nitrogen, worsening renal function, obesity, advanced age, and significant comorbidity are associated with greater risk. C-reactive protein is a commonly studied biomarker, but it rises with a delay and is less informative very early in an attack. Newer biomarker and computational prediction methods remain subjects of research. Prognostic studies are difficult to compare when they use different endpoints, such as necrosis, intensive-care admission, persistent organ failure, or death; prediction of one does not necessarily imply accurate prediction of another.
Supportive treatment and nutritional care
Initial treatment is primarily supportive because no broadly established drug reverses the core inflammatory process in routine acute pancreatitis. Clinical care addresses circulatory perfusion, pain, oxygenation, electrolyte disturbances, and evolving organ dysfunction. The intensity of monitoring varies with physiological instability and disease trajectory. Severe cases may require critical-care support, including mechanical ventilation, vasopressors, or renal replacement therapy. These measures support failing organs while the underlying inflammatory injury evolves.
Intravenous crystalloid fluid replaces losses associated with vomiting, reduced intake, and movement of fluid into tissues. However, fluid administration has competing risks: inadequate replacement can worsen hypoperfusion, whereas excessive administration can promote pulmonary edema and intra-abdominal hypertension. Balanced crystalloids, particularly lactated Ringer solution, have been extensively studied. Contemporary practice emphasizes reassessment of perfusion and fluid tolerance rather than an assumption that all patients benefit from large fixed volumes.
The WATERFALL randomized controlled trial, published in 2022, compared aggressive with moderate early fluid resuscitation. It was stopped early because fluid overload occurred more frequently with the aggressive strategy, approximately 20.5% versus 6.3%, without improvement in the principal clinical outcome. Patients with important baseline organ failure or relevant comorbidities were excluded, which limits direct extrapolation to every critically ill population. The trial nevertheless challenged the longstanding concept that routine aggressive hydration is inherently protective in acute pancreatitis.
Analgesia commonly includes opioid medicines, with other agents used according to the clinical setting. Antiemetic treatment and correction of electrolyte abnormalities are also part of supportive care. Historical concern that morphine would worsen pancreatitis through effects on the sphincter of Oddi has not established a clinical basis for excluding it categorically. Pain treatment is important for comfort and respiratory function, but symptom improvement alone does not demonstrate resolution of organ dysfunction or local complications.
Nutritional care has changed substantially. Prolonged fasting to “rest the pancreas” is no longer the default approach. In mild disease, oral feeding often resumes early as tolerated, and a low-fat solid diet need not be preceded by a sequence of clear liquids. When oral intake is not feasible, enteral nutrition through a gastric or intestinal tube generally has advantages over exclusive parenteral nutrition, including fewer infectious complications in relevant patient groups. Nasogastric feeding is feasible in many cases; a nasojejunal route is useful in selected circumstances. Intravenous nutrition retains a role when the gastrointestinal route cannot provide sufficient intake.
Treatment of biliary disease and other causes
Biliary pancreatitis raises two separate treatment questions: whether there is an infected or persistently obstructed bile duct, and how to prevent further gallstone migration. Endoscopic retrograde cholangiopancreatography, or ERCP, can decompress the biliary system and remove ductal stones, but it is an invasive procedure with its own risks. Urgent ERCP is used when pancreatitis is accompanied by acute cholangitis, an infection associated with biliary obstruction. Routine urgent ERCP has not shown the same benefit in gallstone pancreatitis without cholangitis or continuing obstruction.
Evidence of persistent obstruction may include ongoing jaundice, biochemical abnormalities, or a demonstrated common bile duct stone. Endoscopic ultrasound or magnetic resonance cholangiopancreatography can clarify uncertain cases without the same procedural risks as diagnostic ERCP. This distinction has helped shift ERCP toward a predominantly therapeutic role. A stone that initiated pancreatitis may already have passed, so a biliary cause does not automatically mean that ductal intervention is still required.
Removal of the gallbladder, or cholecystectomy, addresses the principal source of recurrent biliary events. In mild gallstone pancreatitis, surgery during the same hospitalization reduces recurrence compared with postponement. The PONCHO trial, published in 2015, supported this approach in appropriately selected patients. Timing differs in severe necrotizing disease, particularly when significant collections or ongoing inflammation increase operative complexity. Endoscopic biliary sphincterotomy can reduce some recurrent biliary events when gallbladder surgery is not feasible, but it does not remove the gallbladder or prevent all gallbladder-related complications.
Management of alcohol-associated disease includes identifying the exposure and addressing associated withdrawal, nutritional deficiency, and recurrent disease risk within structured care. Tobacco exposure is relevant because it independently contributes to pancreatic disease and may interact with alcohol. Long-term recurrence reflects both the persistence of exposures and individual susceptibility. Assigning alcohol as the cause still requires consideration of alternative or coexisting explanations, including gallstones and severe lipid abnormalities.
In hypertriglyceridemic pancreatitis, treatment also addresses the metabolic disorder and any accompanying hyperglycemia or ketoacidosis. Intravenous insulin lowers triglycerides in selected settings, especially when uncontrolled diabetes is present. Therapeutic plasma exchange can rapidly lower circulating triglycerides, but evidence that routine use improves major clinical outcomes remains limited. For suspected drug-induced disease, causal assessment considers timing, alternative explanations, and prior evidence about the medicine. Recurrent or unexplained episodes may reveal structural obstruction, inherited susceptibility, or autoimmune disease, each of which represents a different treatment problem rather than a uniform category of pancreatitis.
Infection, necrosis, and interventional treatment
Pancreatic necrosis is initially sterile in many patients. Infection can develop later and substantially complicates the course, particularly when persistent organ failure is also present. Clinical deterioration, new or recurrent systemic illness, bloodstream infection, or gas within a necrotic collection can support the diagnosis. Gas is suggestive but not completely specific because communication with the bowel or prior intervention can produce a similar appearance. Fever and elevated inflammatory markers alone cannot reliably distinguish infection from sterile inflammation.
Routine prophylactic antibiotics for sterile necrosis have not shown a consistent benefit in preventing infection or reducing mortality. Antibiotics are used for established or strongly suspected infected necrosis and for infections elsewhere, with selection reflecting likely organisms, tissue penetration, and microbiological results. Sepsis in this setting requires attention both to antimicrobial treatment and to the infected focus. Image-guided needle aspiration is no longer routinely required to confirm every suspected case, partly because clinical and imaging findings may be sufficient and sampling can give false-negative results.
Intervention has moved away from early open removal of necrotic tissue. When the clinical situation permits, delay allows necrosis to become better demarcated and encapsulated, often after approximately four weeks. This makes drainage and removal technically more controlled. Delay is not an absolute rule: uncontrolled infection, bleeding, bowel ischemia, or other emergencies can require earlier action. Conversely, some clinically stable patients with infected necrosis improve with antibiotics and observation without immediate drainage.
The step-up approach begins with the least invasive effective intervention, commonly percutaneous or endoscopic drainage, followed by removal of necrotic material only if necessary. Endoscopic drainage creates a connection between the collection and the stomach or duodenum, often under ultrasound guidance. Percutaneous drainage reaches the collection through the skin. The distribution of necrosis, maturity of the collection, ductal anatomy, patient condition, and local expertise influence the route. Some extensive collections require combined approaches.
The PANTER trial, published in 2010, helped establish this strategy. Major complications or death occurred in approximately 40% of patients assigned to a minimally invasive step-up strategy, compared with 69% assigned to primary open necrosectomy; about 35% of the step-up group were treated with drainage alone. Later trials examined endoscopic approaches and the timing of intervention. Sterile collections may also require treatment when they cause persistent obstruction, pain, nutritional failure, or other significant complications. Diameter alone is not a sufficient indication, and procedures carry risks including bleeding, perforation, fistula formation, and recurrence.
Recovery, recurrence, and long-term consequences
Recovery ranges from a short hospitalization with rapid return of pancreatic function to months of treatment for organ failure and necrotic complications. Persistent organ failure is the strongest central marker of severe disease, while infected necrosis adds substantial complexity and risk. Mortality estimates depend on whether studies include all admissions, only necrotizing disease, or patients with both infection and organ failure. Patients who survive the acute inflammatory phase may still experience prolonged hospitalization, repeated procedures, and loss of physical function.
Endocrine dysfunction can follow acute pancreatitis even in people without pre-existing diabetes. Injury to pancreatic islets, altered insulin secretion, and changes in insulin resistance contribute in varying proportions. Post-pancreatitis diabetes is often classified within diabetes caused by exocrine pancreatic disease rather than automatically being treated as ordinary type 2 diabetes. Studies report widely varying frequencies because follow-up duration, baseline metabolic risk, diagnostic criteria, and disease severity differ. Extensive necrosis and recurrent attacks increase risk, but a mild initial attack does not exclude later diabetes.
Exocrine pancreatic insufficiency results when pancreatic enzyme delivery becomes inadequate for normal digestion. It may produce fatty stools, weight loss, and deficiencies of fat-soluble vitamins. Some early impairment improves as inflammation resolves; persistent insufficiency is more likely after extensive tissue destruction or progression to chronic disease. Symptoms are not entirely specific, and available tests have limitations, particularly in mild dysfunction. Endocrine and exocrine deficits can coexist because the same episode may injure both hormone-producing and digestive tissue.
Pancreatic duct disruption is another cause of prolonged morbidity. In disconnected pancreatic duct syndrome, a viable portion of the gland continues to secrete but has lost continuity with the main drainage pathway because an intervening segment has been destroyed. The result can be recurrent collections, persistent external drainage, or pancreatic ascites. This differs from a simple fluid collection that resolves as the acute inflammation subsides and can require a distinct endoscopic or surgical strategy.
Long-term outcomes also include recurrent attacks, chronic pancreatitis, persistent abdominal pain, fatigue, and reduced health-related quality of life. Survivors of prolonged critical illness may have muscle weakness and limitations in daily activity independent of pancreatic function. Research therefore increasingly measures recurrence, nutritional status, new diabetes, functional recovery, and patient-reported outcomes rather than hospital survival alone. Differences in follow-up duration and outcome definitions remain major obstacles to estimating the full lasting burden of an episode.